创新赛道升温,恒瑞、百济等药企集体加码研发

制药网
Mar 13

近年来,在政策、资本、产业动能三重共振下,中国创新药迎来了“春天”,有诸多药企凭借创新药实现了业绩新增。值得一提的是,在此背景下,恒瑞、百济等大批药企都表示将持续加大研发,聚焦GLP‑1、肿瘤、ADC、AI 制药等核心赛道。3月12日消息 ,福元医药在接受调研者提问时表示,公司重视研发创新,近年来研发投入占比均达到营业收入百分之十以上。公司推进“仿创结合”的研发策略,随着公司创新药项目的持续推进,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10